References from High-dose short-interval canakinumab therapy for mevalonate kinase deficiency associated with novel MVK variants. Local targets link to admitted publications; unresolved targets remain external evidence.
No reference evidence is available for this admitted work.
References for High-dose short-interval canakinumab therapy for mevalonate kinase deficiency associated with novel MVK variants | ResearchHub - ResearchHub
